Concepedia

Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma

Christina Heemann, Markus Kreuz, Irene Stoller, Nils Schoof, Frederike von Bonin, Marita Ziepert, Markus Löffler, Wolfram Jung, Michael Pfreundschuh, Lorenz Trümper,

Clinical Cancer Research · 2012 · 33 citations · 43 references

DOIFull text

Open access

Abstract

Our findings suggest a critical role for TNF-TNFR signaling for the clinical outcome of patients with peripheral T-NHLs.

References

43

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

, , +7

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Michael Pfreundschuh · Blood · 2004 · 716 citations · Full text

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

Norbert Schmitz, Lorenz Trümper, Marita Ziepert et al. · Blood · 2010 · 588 citations · Full text

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL

Michael Pfreundschuh · Blood · 2004 · 479 citations

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

Christian Gisselbrecht, Philippe Gaulard, Éric Lepage et al. · PubMed · 1998 · 438 citations